Companies in the healthcare industry in particular are often known for producing steady performance even in a tough macro period as they aren't exposed to the same economic cyclicality that other industries are. Vertex Pharmaceuticals (NASDAQ: VRTX) is a healthcare company that specializes in medicines and therapies targeting rare diseases. Right now, the company's approved medicines are all for the rare genetic disease cystic fibrosis, and it controls the lion's share of this multibillion-dollar market with its four products that treat the ailment.
If you want solid healthcare stocks that will be worth buying and holding for the next 10 years, you need to set the bar pretty high. But thanks to its portfolio and late-stage pipeline therapies, its next few years should feature strong growth.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $313.57, marking a +0.56% move from the previous day.